Cerebrolysin
| Clinical data | |
|---|---|
| Other names | FPF-1070 |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
Cerebrolysin (developmental code name FPF-1070) is a mixture of enzymatically treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).
Cerebrolysin has also been studied for potential use with a wide variety of neurodegenerative disorders, though research is preliminary.[1] No benefit in the treatment of acute stroke has been found and an increased rate of spontaneous adverse events requiring hospitalization is reported.[2] Some positive effects have been reported when cerebrolysin is used to treat vascular dementia.[3]
Research
Stroke
Reviews emphasize the need for further high quality studies.[2] In addition, use might be associated with a higher rate of spontaneous adverse events requiring hospitalization.[2] Studies of ischemic stroke in Asian subpopulations found an absence of benefit.[4]
A 2020 study suggested a lack of benefit in
Dementia
Reviews of preliminary research indicate a possible improvement in cognitive function using cerebrolysin for vascular dementia and Alzheimer's disease, although further high-quality research is needed.[3][6]
Other
Early studies have suggested potential use of cerebrolysin with a wide variety of neurodegenerative disorders, including traumatic brain injury,[7][8] schizophrenia,[9] multiple sclerosis,[10] cerebral palsy[11] and spinal cord injury[12][13] though research is still preliminary.
Adverse effects
In trials studying the use of cerebrolysin after acute stroke, there was no increased risk of "serious adverse events" requiring hospitalization. These were specifically defined as:
- "...any untoward medical occurrence that, at any dose, resulted in death, [was] life‐threatening, required inpatient hospitalisation or resulted in prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, [was] a congenital anomaly/birth defect, or [was] a medically important event or reaction”.[14]
Mechanism of action
In vitro and animal studies suggest neurotrophic effects of cerebrolysin similar to endogenous neurotrophic factors, though its specific molecular pharmacodynamics are not clear.
Regulatory
Cerebrolysin is not a scheduled drug in the United States.[17][18]
References
- PMID 9700665.
- ^ PMID 37818733.
- ^ PMID 31710397.
- S2CID 26004422.
- PMID 33143640.
- S2CID 245311001.
- PMID 30643411.
- S2CID 3980956.
- S2CID 206397952.
- PMID 28139626.
- S2CID 3805375.
- S2CID 23283518.
- PMID 22229324.
- PMID 32662068.
- PMID 19848437.
- S2CID 23181962.
- ^ Rogers S (29 October 2020). "Nicholasville compounding pharmacy, owner plead guilty to distribution". ABC 36 News.
- ^ "Nicholasville Compounding Pharmacy and Its Owner Sentenced for Unlawful Distribution of Prescription Drugs Unlawful Distribution of Prescription Drugs". www.justice.gov. 24 February 2021.